Last updated on October 2018

A Study Evaluating ABI-H0731 as Adjunctive Therapy in Patients With Chronic Hepatitis B

Brief description of study

The purpose of this study is to determine if ABI-H0731 given in combination with a standard of care HBV medication is safe and effective in patients with chronic hepatitis B.

Detailed Study Description

This is a Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731 as Adjunctive Therapy in Virally-suppressed Patients with Chronic Hepatitis B

Clinical Study Identifier: NCT03576066

Contact Investigators or Research Sites near you

Start Over

Assembly Biosciences

NYU Langone Health
New York, NY United States
  Connect »

Assembly Biosciences

Icahn School of Medicine at Mount Sinai
New York, NY United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.